Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Htut on Immunotherapy in Multiple Myeloma

May 25th 2018

Maung Myo Htut, MD, assistant clinical professor of hematology and hematopoietic cell transplantation, City of Hope, discusses the use of immunotherapy in the treatment of patients with multiple myeloma.

Ofatumumab Combo Falls Short in Indolent Non-Hodgkin Lymphoma

May 25th 2018

Adding ofatumumab (Arzerra) to bendamustine (Treanda) failed to improve progression-free survival in patients with indolent B-cell non-Hodgkin lymphoma who did not respond to rituximab (Rituxan) monotherapy.

New Strategies Aim at Survival Protein MCL-1

May 24th 2018

Myeloid cell leukemia 1 has emerged as an intriguing target for anticancer drug development as researchers turn their attention to strategies directed at evasion of apoptosis.

Expert Addresses Advances and Challenges in MDS

May 24th 2018

Jing Ai, MD, discusses the treatment of patients with myelodysplastic syndrome.

Expert Weighs Treatment Methods in Hodgkin Lymphoma

May 22nd 2018

Nilanjan Ghosh, MD, PhD, discusses the advances and ongoing research in frontline treatment of patients with Hodgkin lymphoma.

Stemness Inhibitor Tested in Rare Hematologic Cancer

May 17th 2018

SL-401, a novel therapy that targets a cancer stemness pathway, is being investigated in patients with blastic plasmacytoid dendritic cell neoplasm in a phase I/II trial.

Dr. Ghosh on Frontline Immunotherapy in Hodgkin Lymphoma

May 17th 2018

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses frontline immunotherapy in Hodgkin lymphoma.

Nelarabine Boosts 4-Year DFS Above 90% in Pediatric/AYA T-Cell Cancers

May 17th 2018

Adding nelarabine to escalating-dose methotrexate induced a 4-year disease-free survival rate of 91% in a cohort of pediatric and young adult patients with newly diagnosed T-cell cancers.

FTase Inhibition Holds Promise for RAS Targeting and Beyond

May 16th 2018

Although mutant RAS has proved to be a challenging therapeutic target, recent success with tipifarnib, a biologically active drug known as a farnesyltransferase inhibitor, brings promise for treating solid tumors and hematological malignancies.

Inaugural Guidelines for Patients With HIV Aim to Expand Therapy Options

May 12th 2018

Specific guidance in the HIV-infected population was not previously available, partly because persons living with HIV were previously excluded from cancer clinical trials, creating a knowledge gap.

Oral Anticoagulants Make Welcome Addition to VTE Patient Care

May 10th 2018

The NCCN guideline committee has designated a direct oral anticoagulant as a preferred frontline treatment for most patients with cancer-associated venous thromboembolism.

Dr. Jacobs on the Efficacy of Ibrutinib and Acalabrutinib in Patients With MCL

May 9th 2018

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the efficacy of ibrutinib (Imbruvica) and acalabrutinib (Calquence) in patients with mantle cell lymphoma (MCL).

Quizartinib Improves Survival in FLT3-ITD+ Relapsed/Refractory AML

May 8th 2018

Quizartinib improved overall survival compared with chemotherapy in patients with FLT3-ITD–positive relapsed/refractory acute myeloid leukemia after first-line treatment with or without hematopoietic stem cell transplantation, according to findings from the phase III QuANTUM-R study.

Role of Checkpoint Inhibition in Most Hematologic Cancers Unclear, But Potential Remains

May 8th 2018

Saad Z. Usmani, MD, discusses the current state of immune checkpoint inhibitors in hematologic cancers, recent setbacks, and ongoing studies that could further shape the landscape.

Novel Agents Advance Acute Leukemia Treatment, But Challenges Remain

May 8th 2018

Michael R. Grunwald, MD, discusses new and emerging agents in acute myeloid leukemia and acute lymphoblastic leukemia, as well as sequencing and toxicity challenges with these treatments.

Dr. Ai on the Use of Hypomethylating Agents in Patients With MDS

May 7th 2018

Jing Ai, MD, physician, Levine Cancer Institute, discusses the use of hypomethylating agents in patients with myelodysplastic syndrome (MDS).

Dr. Ghosh on the Future of CAR T-Cell Therapy in Patients With Hematologic Malignancies

May 7th 2018

Nilanjan Ghosh, MD, PhD, physician, Levine Cancer Institute, discusses the future of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with hematologic malignancies.

NICE Recommends Midostaurin for FLT3+ AML

May 4th 2018

The National Institute for Health and Care Excellence has authorized the use of midostaurin in combination with standard chemotherapy for the treatment of patients with newly diagnosed FLT3-positive acute myeloid leukemia.

CAR T-Cell Therapy May Serve as a Bridge to HCT in ALL

May 3rd 2018

CAR T-cell therapy can induce next generation sequencing negativity in patients with relapsed/refractory acute lymphoblastic leukemia, suggesting a "synergistic" relationship with hematopoietic cell transplant.

Dr. Rosenzweig Discusses the Standard of Care in Amyloidosis

May 2nd 2018

Michael Rosenzweig, MD, assistant professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope, discusses the standard of care for the treatment of patients with amyloidosis.